Jaguar Health, Inc. is a specialty pharmaceutical company focused on developing and commercializing sustainably derived, plant-based prescription drugs for gastrointestinal disorders in humans and animals. Operating primarily through its wholly owned subsidiary Napo Pharmaceuticals, Inc., the company targets unmet medical needs in complex gastrointestinal disease states, including rare and orphan conditions. Jaguar Health also collaborates with Filament Health Corp. through the joint venture Magdalena Biosciences to explore plant-based therapies for mental health indications, such as adult attention-deficit/hyperactivity disorder. The company’s pipeline centers on crofelemer, a novel anti-secretory agent extracted from the Croton lechleri tree, which normalizes electrolyte and fluid balance in the gastrointestinal tract.

The company generates revenue primarily through the sale of its FDA-approved prescription products and licensing agreements. Its flagship product, Mytesi (crofelemer 125 mg delayed-release tablets), is approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. In January 2026, Jaguar licensed U. S. commercialization rights for Mytesi and Canalevia-CA1, its chemotherapy-induced diarrhea treatment for dogs, to Future Pak, LLC, securing $16 million in non-dilutive capital and potential milestone payments of up to $20 million. Additionally, Jaguar launched Gelclair, an oral mucositis prescription gel, in the U. S. market in October 2024. The company also earns revenue from manufacturing crofelemer for its licensees and through international distribution agreements, such as those with Quadri Pharmaceuticals Store LLC in the Middle East and Knight Therapeutics Inc. in Canada and Israel.

The company operates through the following segments:

• Human Health: This segment focuses on the development and commercialization of crofelemer-based therapies for gastrointestinal disorders in humans. Key programs include Mytesi for HIV-related diarrhea, crofelemer powder for oral solution for rare pediatric and adult intestinal failure conditions such as microvillus inclusion disease and short bowel syndrome, and NP-300, a second-generation anti-secretory drug for infectious diarrhea, including cholera. The segment also encompasses the commercialization of Gelclair for oral mucositis in cancer patients.

• Animal Health: This segment develops and markets gastrointestinal therapies for companion animals, primarily dogs. Its lead product, Canalevia-CA1 (crofelemer delayed-release tablets), is conditionally approved by the FDA for the treatment of chemotherapy-induced diarrhea in dogs. The segment operates under the Jaguar Animal Health tradename and continues to explore additional indications for crofelemer in veterinary medicine.

• Mental Health (Magdalena Biosciences): This segment, a joint venture with Filament Health Corp., focuses on developing novel, plant-based prescription medicines for mental health disorders. The initial target is adult attention-deficit/hyperactivity disorder, leveraging Jaguar’s proprietary library of medicinal plants and Filament’s drug development technology.

Jaguar Health occupies a distinctive position in the gastrointestinal pharmaceutical industry, targeting niche and underserved markets with first-in-class, plant-derived therapies. Its primary competitive advantage lies in crofelemer’s unique mechanism of action, which modulates intestinal chloride ion secretion to normalize fluid and electrolyte balance, addressing conditions where existing treatments are limited or nonexistent. In the rare disease space, crofelemer powder for oral solution is positioned as a paradigm-shifting therapy for microvillus inclusion disease and short bowel syndrome, conditions currently managed with lifelong parenteral support. Competitors in this segment include Takeda Pharmaceuticals, which markets GATTEX (teduglutide) for short bowel syndrome, though crofelemer’s earlier administration post-surgery and broader patient eligibility provide a differentiating edge. For infectious diarrhea, NP-300 aims to fill a gap where no FDA-approved anti-secretory drugs exist, competing with standard oral rehydration salts and antibiotics. The company’s intellectual property portfolio, comprising approximately 195 patents with expirations extending to 2031, further strengthens its market position by securing exclusivity for its innovations.

The company serves a diverse customer base across its segments. In human health, its primary customers include adults with HIV/AIDS experiencing noninfectious diarrhea, cancer patients undergoing chemotherapy or targeted therapies, and individuals with rare gastrointestinal disorders such as microvillus inclusion disease and short bowel syndrome. Gelclair targets cancer patients suffering from oral mucositis. In animal health, the customer base consists of veterinarians and pet owners, particularly those managing dogs with chemotherapy-induced diarrhea. While specific customer names are not disclosed, Jaguar’s products are distributed through partnerships with specialty pharmaceutical companies, including Future Pak in the U. S. and Knight Therapeutics in Canada and Israel. The company also engages with healthcare providers, hospitals, and clinics globally, particularly in regions with high unmet medical needs.